Carsten Thiel Announced As New Regional Vice President For Amgen (AMGN)'s Europe And Australia Business

Carsten Thiel Announced As New Regional Vice President For Amgen (AMGN)'s Europe And Australia Business


ZUG, December 9, 2010 -- The European and Australian operations of the world's largest independent biotechnology company, Amgen, will be under new leadership from January 2011.

The current general manager of Amgen's German affiliate, Dr Carsten Thiel will take up the position of Regional Vice President, Europe and Australia, and move to the company's international headquarters in Zug, Switzerland.

To facilitate the company's broadening global footprint, this new role will report to Rolf Hoffmann. Hoffmann will continue to manage Amgen's international business and will also be responsible for all Amgen's activities outside the USA. He will move from Switzerland to the company's headquarters in Thousand Oaks, California.

Born in Germany, Thiel studied chemistry at the University of Marburg and obtained a doctorate in molecular biology from Max-Planck Institute in Goettingen. He started his professional career at Hoffmann-La Roche in Germany, then assumed various national and international management positions. Thiel continued his career at Eurofins Scientific in Belgium as International Marketing Director.

In 2002, Thiel moved to Amgen's international headquarters where he first managed the Oncology Department and was later appointed General Manager responsible for the Eastern European markets. He was appointed as General Manager of Amgen in Germany in 2007.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com .
 

 

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.